ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

UK Health Body Approves Novartis's Gilenya For MS

ZURICH -(Dow Jones)- The U.K.'s health-cost regulator is backing Novartis's (NVS) pill Gilenya for certain adult patients with highly active relapsing-remitting multiple sclerosis. The independent National Institute for Clinical Excellence, known by its acronym NICE, said Wednesday it is recommending Gilenya, or fingolimod, for use on the publicly funded National Health Service. "We are pleased to recommend fingolimod as a treatment option for the specific patient population for whom it has been demonstrated to be cost-effective, providing Novartis applies its proposed discount," NICE Director Carol Longson said, without disclosing the price. Gilenya has been available in the European Union since March 2011 for treating relapsing-remitting MS, the most common type of the disease. The drug was approved in the U.S. in 2010. Novartis hopes the drug will become one of the leading treatments in the multibillion-dollar market for treating MS due to its easy oral use. "Novartis welcomes this final decision from NICE, which will allow appropriate patients with highly active relapsing-remitting MS to have access to Gilenya under the NHS in England and Wales," the company said in a statement, adding that it "remains committed to engaging with reimbursement authorities with the goal of ensuring that appropriate patients will have access to the treatment." Last week, EU and US regulators requested stronger label warnings for Gilenya after conducting reviews of the pill's safety, following reports of heart problems and the death of a patient. -By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; marta.falconi@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
04/10/201412:25:40Zurich Stocks See Gains
04/09/201408:34:24Novartis Names New Alcon, Sandoz Division Heads -- Update
04/09/201402:50:35Novartis Names New Alcon, Sandoz Division Heads
04/03/201417:12:35ADR Shares End Lower; Vodafone Shares Active
04/02/201416:55:18ADR Shares End Higher; Noah Education Shares Active
03/31/201417:16:48ADR Shares End Higher; ING, Novartis Shares Active
03/31/201412:29:09EUROPE MARKETS: European Stocks End Mixed On Inflation Jitters
03/31/201411:07:25Supreme Court to Review Teva Appeal in Copaxone Patent Case
03/31/201410:29:55EUROPE MARKETS: European Stocks Push Higher After Weak Inflation
03/31/201406:22:12EUROPE MARKETS: European Stocks Pare Gains After Weak Inflation...
03/31/201404:55:55EUROPE MARKETS: European Stocks Firm Ahead Of Inflation Data
03/31/201403:25:12Novartis Heart Failure Pill Trial Ends Early on Positive Result
03/26/201413:54:19EUROPE MARKETS: Europe Stocks Higher As ECB Stokes Stimulus Hopes
03/22/201404:16:47Novartis Chairman Stresses Need for R&D Investment
03/21/201413:26:03Glaxo Wins Battle Over Asthma Drug
03/14/201417:12:21ADR Shares End Lower; GlaxoSmithKline Shares Active
03/14/201412:10:09HSBC Taps Symonds as Chairman of European Retail Unit
03/14/201411:55:38HSBC Appoints Former Novartis CFO as Chairman of European Retail...
03/07/201408:12:10EUROPE MARKETS: European Stocks Head For Weekly Loss Ahead Of...
02/26/201412:40:17Novartis to Shut U.K. Plant, Cut 361 Jobs

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad